Kornimate/medical-research-clean huggingface dataset:
study of cobalt's role in excessive erythrocytosis among high altitude dwellers in cerro de pasco, peru

Conditions: Erythrocytosis; Mountain Sickness

Summary: chronic mountain sickness is characterized by excessive red blood cell production which causes sludging of the vascular system. this high viscosity blood causes heart failure, cognitive dysfunction, and strokes. the investigators hypothesize that cobalt which has been previously been shown to be an environmental pollutant worsens the overproduction of red blood cells. the investigators plan to conduct a 6 week trial in which acetazolamide (already shown to improve chronic mountain sickness) and n-acetylcysteine (a drug that removes cobalt from the blood) are evaluated in their potential to improve chronic mountain sickness.


Eligibility criteria:
inclusion criteria: * males over 17 years of age * hematocrit \> 70% * chronic mountain sickness score (cms) \> 6 * able to give informed consent and follow instructions in written spanish exclusion criteria: * cms \> 15 * underlying lung disease, smoking, or oxygen therapy * asthma (bronchospasm can be caused by n-acetylcysteine) * phlebotomy in last 3 months * h/o adverse reaction to acetazolamide or n-acetylcysteine

Keywords: cobalt excessive erythrocytosis monge's disease acetazolamide n-acetylcysteine altitude sickness chronic mountain sickness
a study of mycobacterium w plus docetaxel for hormone refractory metastatic prostate cancer

Conditions: Hormone Refractory Prostate Cancer

Summary: this study proposed the comparison the overall survival, hematological toxicity, pain reduction score,psa levels, tumor response, quality of life in two arms of hrpc patients from different parts of india.

prostate cancer is a common health issue facing men worldwide in most of the patients cancer will shrink with hormonal therapy. in some cases cancer returns or continues to grow despite very low levels of circulating male hormones, which is called androgen-independent prostate cancer (aipc) or hormone refractory prostate cancer (hrpc). mycobacterium w is known to share multiple antigen including psa. it administration is associated with antigen specific generation of cell mediated immunity. docetaxel is found to useful in management of metastatic hormone refractory prostate cancer, which is associated with improved survival, tumor progression free survival with reduction in pain, serum psa and improvement in quality of life. cyclophosphamide 300mg/sq.m will be used to eliminate t-regulatory cell responsible immuno suppression. the vaccine mycobacterium w will be administered on a day following cyclophosphamide. for better initiation of immune responses docetaxel will be given seven days following first dose of mycobacterium w.

Eligibility criteria:
inclusion criteria: * histologically or cytologically confirmed adenocarcinoma of the prostate with clinical or radiologic evidence of metastatic disease. * disease progression during antiandrogen therapy, having surgical or medical castration status. * karnofsky performance status 50-100 * normal cardiac function * life expectancy at least 24 weeks. * laboratory criteria for eligibility will include * a neutrophil count of at least 1500 per cubic millimeter * a hemoglobin level of at least 9 gm% * a platelet count of at least 1000,000 per cubic millimeter. * a total bilirubin not grater than 1.5 times the upper limit of the normal range for each institution. * serum creatinine levels not more than 1.5 times the upper limit of the normal range * written informed consent exclusion criteria: * prior treatment with cytotoxic agents or radioisotopes * estrogen use for at least three months * history of another cancer within the preceding five years (except basal or squamous-cell skin cancer) * brain or leptomeningeal metastases * symptomatic peripheral neuropathy of grade 2 or higher * uncontrolled intercurrent illness that would limit compliance with study requirements

Keywords: hrpc metastatic hormone refractory prostate cancer docetaxel mycobacterium w
resilient living program for patients with advanced cancer and their caregivers

Conditions: Advanced Cancer

Summary: researchers are trying to find out if the resilient living program will improve quality of life, stress, anxiety, sleep, fatigue, and resilience in patients with advanced cancer and their caregivers.


Eligibility criteria:
inclusion criteria for patients: * age ≥18 years * english fluency * no diagnosed severe cognitive impairment * diagnosis of stage iv solid tumor cancer * expected prognosis \>6 \<18 months * provide written informed consent * ability to complete questionnaire(s) by themselves or with assistance * patient baseline distress score ≥4/10 or identified as having distress that would benefit from program by care team or provider * ability to do first resilient living session in person inclusion criteria for caregivers: * self-identifies as a caregiver of a patient that meets the above cancer diagnosis criteria, and who also participates in the study * provide written informed consent * ability to complete questionnaire(s) by themselves or with assistance * age ≥18 years * english fluency * no diagnosed severe cognitive impairment * ability to do first resilient living session in person exclusion criteria: * as determined through self-report, those diagnosed with a history of a psychotic episode will be excluded. * other psychological co-morbidities such as untreated schizophrenia, bipolar disease
effect of preoperative chemoradiotherapy on exercise capacity as measured by cardiopulmonary exercise testing

Conditions: Colorectal Cancer

Summary: this study will investigate the effect of preoperative chemoradiotherapy on exercise capacity as measured by cardiopulmonary exercise testing in patients with colorectal cancer.

chemoradiotherapy is associated with adverse effects. patients with certain colorectal cancers undergo chemoradiotherapy prior to surgical resection. we intend to assess patient exercise capacity before and after chemoradiotherapy to assess whether this deteriorates. if there is a deleterious effect, this may affect operative outcome.

Eligibility criteria:
inclusion criteria: * age greater than 65 * colorectal cancer requiring preoperative chemoradiotherapy exclusion criteria: * inability to walk, or exercise on a bicycle or treadmill * inability to understand instructions for cpet testing * asa grade 4 or 5 (indicating severe cardiovascular co-morbidity and not expected to survive surgery) * contraindications to exercise testing * myocardial infarction occurring 10 days or less before cpx testing * symptomatic arrythmias * left main stem coronary disease of \>50% * severe hypertension (sbp\>180mmhg) * resting spo2 \<85% * acute cardiac inflammatory conditions (myocarditis, pericarditis) * unstable angina with symptoms within 4 days * dissecting aneurysm of aorta * acute pyrexial illness * thyrotoxicosis * syncopal episodes * lower limb thrombosis (arterial or venous)

Keywords: exercise capacity chemoradiotherapy colorectal cancer
eus-guided gallbladder drainage instead of laparoscopic cholecystectomy for acute cholecystitis. a feasibility study.

Conditions: Acute Cholecystitis

Summary: to evaluate the feasibility of performing egbd as a treatment of acute calculous cholecystitis in patients that are indicated for laparoscopic cholecystectomy.

the gold standard for treatment of acute calculous cholecystitis is laparoscopic cholecystectomy. recently, gallbladder drainage with eus-guided gallbladder drainage (egbd) has been described as a treatment option. however, whether this is an effective treatment option in surgically fit patients are uncertain. the aim of the current study is to evaluate the feasibility of performing egbd as a treatment of acute calculous cholecystitis in patients that are indicated for laparoscopic cholecystectomy. the investigators hypothesis that the technique is safe and feasible.

Eligibility criteria:
inclusion criteria: consecutive healthy patients aged ≥ 18 years old suffering from acute calculous cholecystitis indicated for laparoscopic cholecystectomy would be included. exclusion criteria: * pregnancy * patients unwilling to undergo follow-up assessments * patients with suspected gangrene or perforation of the gallbladder * patients diagnosed with concomitant liver abscess or pancreatitis (defined as elevated serum amylase more than three times the upper limit of normal) * patients with duodenal obstruction * altered anatomy of the upper gastrointestinal tract due to surgery of the esophagus, stomach and duodenum * patients with liver cirrhosis, portal hypertension and/or gastric varices * abnormal coagulation: international normalised ratio (inr) \> 1.5 and/or platelets \< 50.000/mm3 * previous drainage of the gallbladder

Keywords: acute cholecystitis eus-guided gallbladder drainage laparoscopic cholecystectomy gallbladder polyp gallstone
safety and effectiveness of disposable pulmonary surgical markers in the localization of pulmonary nodules

Conditions: Lung Cancer

Summary: during the vats procedure, some pulmonary nodules are relatively small or far away from the pleura, resulting that they are difficult to be accurately located during the procedure. the aim of this study is to evaluate the efficacy and safety of using disposable pulmonary surgical markers to localize pulmonary nodules in subjects prior to the resection of pulmonary nodules by video-assisted thoracoscopic surgery (vats).

it is a prospective, multicenter, single group target value clinical trial. the subjects will undergo vats within 24h after the placement of the marker, then the marker and targeted nodule will be removed during vats. subjects will be followed up intraoperatively, immediately after placement procedure to the end of vats resection, 7 days after placement procedure/before discharge (whichever occurs earlier), and 30 days after marker placement procedure. demographic and baseline information of subjects, immediate operation success rate of marker placement, positioning success rate, and adverse events will be collected and recorded in this study.

Eligibility criteria:
inclusion criteria: * age 18-70 years old； * pulmonary nodule, which satisfying any of the following criteria: * solid nodules with diameter ≤1 cm or solid component ≤1 cm non-purely ground glass, and the distance between the solid component of the nodule and the visceral pleural\>0.5cm; * pure ground glass opacity (pggo)； * before vats operation, the doctor judge that the nodule is difficult to locate during the operation. * pulmonary wedge resection or segmental pulmonary resection under vats is proposed; * preoperative evaluation shows that placing marker through bronchus is feasible； * the subject is able to fully understand the requirements of clinical research; * subject or the legal representative signs the informed consent form. exclusion criteria: * contraindications for bronchoscopy; * systemic factors: sepsis, history of repeated pulmonary infections, and any type of severe infectious disease within one month of screening； * severe cardio and pulmonary disease； * coagulation dysfunction, with a clear tendency to bleed; * general anesthesia contraindication; * allergic history of nickel-titanium materials; * breast-feeding or may be or plan to be pregnant during the trial; * participating in clinical trials of other drugs or medical devices; * other conditions that investigator consider the subject to be inappropriate.

Keywords: pulmonary nodule localization marker
analgesic effect of levobupivacaine in breast augmentation

Conditions: Pain

Summary: the purpose of this study is to determine whether levobupivacaine is effective in the acute postoperative pain treatment in periprosthetic breast augmentation

one of the most common plastic surgery is breast augmentation using prosthesis ( mammoplasty surgery with cohesive silicone gel prosthesis insubpectoral plane). remains challenging management of acute postoperative pain that allows for early discharge of patients. to this end the following objectives are proposed: evaluate the analgesic efficacy of l-bupivacaine 0.25% vs. placebo (saline) administered irrigation into the surgical pocket bilaterally intraoperatively.

Eligibility criteria:
inclusion criteria: * women\> 18 and \<= 65 years * mammoplasty surgery with cohesive silicone gel prosthesis in subpectoral plane * asa i and ii * informed consent signed exclusion criteria: * rejection of the patient * asa iii or higher * other conditions that warrant their inclusion as medically indicated (eg psychiatric illness). * allergy to nsaids, local anesthetics and / or morphine * patients treated for chronic pain * placement of drains for surgical needs

Keywords: postoperative patient-reported
sleeve gastrectomy with cruroplasty and omental rape for treatment of morbid obesity with reflux disease

Conditions: Obesity, Morbid; GERD

Summary: in this study the investigators will test anew technique to mange patients with morbid obesity and gerd by doing sleeve gastrectomy plus cruroplasty and omental rape around the gastroesophageal junction

in this study the patients that have morbid obesity concomitant gerd will managed by sleeve gastrectomy plus cruroplasty then stripe from the momentum is fashioned and is raped around the gastroesophageal junction

Eligibility criteria:
inclusion criteria: * obese patients with bmi more than 40 with or without co-morbidity or more than 35 with co-morbidity * patients fit for laparoscopic surgery * give approval to share in the study exclusion criteria: * patients refused to share in the study * patients unfit for surgery * patients aged less than 18 and older than 60 * patient with previous upper abdominal surgery either for obesity or other diseases * revisional bariatric procedures
experimental evaluation of back braces for the treatment of spinal deformity produced with 3d printing technology

Conditions: Adolescent Idiopathic Scoliosis; Osteogenesis Imperfecta

Summary: the proposed investigation is a pilot study that involves pediatric patients affected by spinal deformity (adolescent idiopathic scoliosis and osteogenesis imperfecta). the main goal is to evaluate the acceptability, the safety and the overall satisfaction of the patients wearing the back braces produced with an innovative methodology using 3d printers, compared to the current braces manufactured with a production model based on thermoforming, that has well-established clinical efficacy.


Eligibility criteria:
inclusion criteria for adolescent idiopathic scoliosis: * ages 6 to 17 years; * lumbar or thoracolumbar scoliosis; * measured rib hump greater than 5 degrees with scoliometer; * cobb angle, measured on frontal x-ray images, within 15 and 30 degrees. inclusion criteria for osteogenesis imperfecta: * ages 3 to 17 years; * vertebral pain and/or vertebral deformity with typical double-concave lenses shape and/or deformity in frontal or sagittal planes assessed with clinical traction, deflection or derotational tests. exclusion criteria: * skin allergies; * behavioural and psychiatric problems (e.g., emotional problems, anxiety, panic); * chest dimensions beyond printing limits (i.e., maximum diameter 35 cm and maximum height 60 cm).

Keywords: scoliosis spinal deformity
alfuzosin versus placebo in acute urinary retention

Conditions: Urinary Retention

Summary: the primary objective of the study is to investigate if 14 days of treatment with alfuzosin compared to placebo, will increase the number of patients with satisfying spontaneous voiding after acute urinary retention treated with clean self-catheterization. furthermore is investigated the safety of the medical treatment and self-catheterization.


Eligibility criteria:
inclusion criteria: * men with acute urinary retention and catheterized * benign hypertrophia of prostate * patient is diagnosed in emergency room or at a acute hospitalization exclusion criteria: * known prostate cancer * prior urinary retention within 30 days * urinary retention occurring in relation to surgery * blood in urine * difficult or impossible catheterization * fever \> 38 degree celsius * decreased kidney function * permanent catheter \> 14 days * treatment with alfa 1 blocker within 30 days * meeting contraindications to treatment with alfuzosin * treatment with other drugs for urinary problems the above information is not intended to contain all considerations relevant to a patients potential participation in a clinical trial.
timing of rocuronium after induction with propofol on temporal summation of pain

Conditions: Gynecological Disorder

Summary: temporal summation of pain, which is defined as the perception of increasingly greater pain evoked by repetitive painful stimuli, is highly variable between individuals. this study aimed to determine the impact of the timing of rocuronium after induction with propofol on temporal summation of pain in gynecologic laparoscopic surgery.


Eligibility criteria:
inclusion criteria: * elective gynecologic laparoscopic surgery * american society of anesthesiologists' physical status class) i-ii exclusion criteria: * menopause (to exclude the hormonal effect on pain) * patients who had muscular, cardiovascular, hepatic or kidney disorders and patients with a history of medication who would affect muscle relaxants were excluded from this study. * patients with difficult venous access on forearm, a known allergy to propofol or rocuronium, chronic pain, pregnancy, and those who had received analgesics or sedatives within the previous 24 hours, were excluded from the study.

Keywords: pain, propofol, rocuronium, temporal summation.
whole-body vibration for functional constipation

Conditions: Constipation

Summary: 1. aim: the aim of this trial was to determine whether whole-body vibration (wbv) induced via a non-invasive oscillation platform could improve symptoms and health-related quality of life (hrqol) in patients with chronic functional constipation. 2. methods: a single-blinded, randomized, control trial was performed in a single hospital in taiwan. patients diagnosed with chronic functional constipation, as per the rome iii diagnostic criteria were included and randomized to either the wbv treatment or no treatment (control) group. the treatment group received six 15-minute sessions of wbv therapy over a two-week period. patients received vibrations of 2 mm in amplitude at a frequency of 12 hz. the primary outcome was assessed by the constipation severity instrument (csi). the secondary outcome was improvements in hrqol.


Eligibility criteria:
inclusion criteria: * met the rome iii criteria of constipation exclusion criteria: * pregnant * cardiovascular disease * cerebrovascular disease * recently undergone major surgery * hypothyroidism * depressive disorder.
safety and efficacy study of nggt001 in bietti crystalline corneoretinal dystrophy

Conditions: Bietti's Crystalline Dystrophy

Summary: evaluate the safety and tolerability of nggt001 subretinal injection for the treatment of crystalline retinal degeneration (bcd)


Eligibility criteria:
inclusion criteria: 1. age ≥ 18 years old; 2. gender unlimited. 3. diagnosed as crystalline retinal degeneration (bcd). 4. molecular diagnosis confirms cyp4v2 mutation. 5. the best corrected visual acuity is less than 20/60. 6. agree to take contraceptive measures within 1 year from the start of the study until administration. 7. voluntarily sign an informed consent form. exclusion criteria: 1. insufficient number of photoreceptor cells in the retina, such as retinal thickness less than 100 μ m. or no atrophy or pigmentation in the posterior pole area\&amp;lt;3- retinal disc. 2. the presence of choroidal neovascularization or other eye lesions caused by bcd, which researchers believe may affect surgical procedures or interfere with the interpretation of clinical endpoints. 3. the use of therapeutic drugs within the first 6 months of enrollment may affect experimental observation, such as lucentis, avastin, conbercept, triamcinolone acetonide, steroids, etc; 4. the treatment eye has undergone intraocular surgery, such as pdt, vitrectomy, periocular vascular bypass surgery, etc., or requires intraocular surgery during clinical research, such as cataract surgery, retinal laser therapy, etc; 5. used or may use systemic medications that may cause eye damage, such as psoralen, tamoxifen, etc; 6. highly sensitive or allergic to the ingredients in the experimental drug (with a history of allergies to two or more drugs or foods); 7. abnormal and clinically significant physical examination, vital signs, laboratory tests (such as blood routine, urine routine, blood biochemistry, coagulation function, immunological tests, etc.), or abnormal indicators deemed clinically significant by researchers; 8. there are diseases or medical histories that may affect drug safety or internal processes, especially cardiovascular, liver, kidney, endocrine, digestive, lung, neurological, hematological, tumor, immune or metabolic disorders that researchers consider clinically significant. 9. participated in clinical trials of other drugs or medical devices within 3 months prior to enrollment; 10. female patients during pregnancy or lactation; 11. other researchers believe that it is not suitable to participate in the study.
bmi development and risk of overweight and obesity in children

Conditions: Health Behavior; Child Obesity; Body Weight

Summary: the goal of this observational study is to investigate differences in attained bmi and the proportion of overweight/obesity at school entrance in children who attended kindergartens actively delivering a community-based health promotion and obesity prevention intervention compared to children who attended usual care kindergartens. further questions it aims to answer are: * explore the prevalence of attainted overweight/obesity in children at six years of age, who attended kindergartens delivering intervention compared with usual care kindergartens. * explore the development of obesity, overweight and normal weight in children from three-, four- to six years of age, who attended kindergartens delivering intervention.


Eligibility criteria:
inclusion criteria: * all children with eligible information on one measure of bmi after school entrance exclusion criteria: * \<7 years of age

Keywords: obesity body mass index children kindergarten